{"nctId":"NCT00432042","briefTitle":"Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)","startDateStruct":{"date":"2007-01-12","type":"ACTUAL"},"conditions":["Varicella","Measles","Mumps","Rubella","Diphtheria","Tetanus","Pertussis","Poliomyelitis","Hepatitis B","Haemophilus Infections"],"count":955,"armGroups":[{"label":"ProQuad® + Infanrix® hexa","type":"EXPERIMENTAL","interventionNames":["Biological: ProQuad®","Biological: Infanrix® hexa"]},{"label":"ProQuad®","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: ProQuad®"]},{"label":"Infanrix® hexa","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Infanrix® hexa"]}],"interventions":[{"name":"ProQuad®","otherNames":[]},{"name":"Infanrix® hexa","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy participants of either gender\n* Aged 12 to 23 months\n* No clinical history of measles, mumps, rubella, varicella and zoster\n* For Italy: Primary vaccination with the combined diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b vaccine Infanrix® hexa as a 2-dose schedule, with receipt of the second dose ≥ 6 months prior to inclusion\n* For Germany: Primary vaccination with the combined diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b vaccine Infanrix® hexa as a 3-dose schedule, with receipt of the third dose ≥ 6 months prior to inclusion\n* Consent form signed by parent(s) according to local regulations or by the legal representative properly informed about the study\n* Parent(s)/legal representative able to understand the protocol requirements and to fill in the Diary Card.\n\nExclusion Criteria:\n\n* Prior receipt of measles, mumps, rubella and/or varicella vaccine either alone or in any combination\n* Any recent (\\<= 30 days) exposure to measles, mumps, rubella, varicella and/or zoster\n* Receipt of any other diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and/or Haemophilus influenzae type b containing vaccine (either alone or in any combination) than Infanrix® hexa\n* Any recent (\\<= 3 days) history of febrile illness\n* Any severe chronic disease\n* Active untreated tuberculosis\n* Known personal history of encephalopathy, seizure disorder or progressive, evolving or unstable neurological condition\n* Any known blood dyscrasia, leukemia, lymphomas of any type, or other malignant neoplasms affecting the haematopoietic or lymphatic systems\n* Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection\n* Prior known sensitivity/allergy to any component of the vaccines including neomycin, sorbitol or gelatin\n* Any immune impairment or humoral/cellular deficiency, neoplastic disease or depressed immunity\n* Any recent (\\<= 2 days) tuberculin test or scheduled tuberculin test through Visit 2\n* Any previous (\\<= 150 days) receipt of immune serum globulin or any blood-derived products or scheduled to be administered through Visit 2\n* Any recent (\\<= 30 days) receipt of an inactivated or a live non-study vaccine or scheduled non-study vaccination through Visit 2\n* Any medical condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives\n* Any recent (≤30 days) participation or scheduled participation in any other clinical trial through Visit 2","healthyVolunteers":true,"sex":"ALL","minimumAge":"12 Months","maximumAge":"23 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Meeting Antibody Response Rate Criteria to Measles, Mumps, Rubella, and Varicella","description":"The percentage of participants with seronegative baseline values who met antibody response criteria in Arm 1: ProQuad® + Infanrix® hexa and Arm 2: ProQuad® was determined. Post-vaccination antibody response and baseline seronegativity criteria were as follows: measles antibody titre ≥255 mIU/mL in participants with baseline titre \\<255 mIU/mL; mumps antibody titre ≥10 ELISA Ab units/mL in participants with baseline titre \\<10 ELISA Ab units mL; rubella antibody titre ≥10 IU/mL in participants with baseline titre \\<10 IU/mL; varicella antibody titre ≥5 gpELISA units/mL in participants with baseline titre \\<1.25 gpELISA units/mL. Measles, mumps and rubella antibody levels were determined using enzyme-linked immunosorbent assay (ELISA) and varicella antibody levels were determined with glycoprotein-based ELISA (gpELISA).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.4","spread":null},{"groupId":"OG001","value":"96.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.7","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.9","spread":null},{"groupId":"OG001","value":"99.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.7","spread":null},{"groupId":"OG001","value":"95.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Meeting Post-vaccination Antibody Response Rates to Hepatitis B and Haemophilus Influenzae Type B","description":"The percentage of participants with seronegative baseline values who met antibody response criteria in Arm 1: ProQuad® + Infanrix® hexa and Arm 3: Infanrix® hexa was determined. Post-vaccination antibody response and baseline seronegativity criteria were as follows: Hepatitis B antibody titre ≥10 IU/mL and Haemophilus Influenzae Type b antibody titre ≥1 ug/mL. Hepatitis B antibody levels were determined using anti-HBs ORTHO ECi Immunodiagnostic Assay. Haemophilus Influenzae Type b antibody (anti-polyribosylribitol phosphate \\[PRP\\]) levels were determined with radioimmunoassay (RIA) or with enzyme immunoassay (EIA).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.5","spread":null},{"groupId":"OG001","value":"98.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null},{"groupId":"OG001","value":"95.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Post-vaccination Geometric Mean Titres (GMT) to Pertussis","description":"The GMT to pertussis were compared in Arm1: ProQuad® + Infanrix® hexa and Arm 3: Infanrix® hexa. Anti-pertussis toxin (anti-PT), anti-filamentous hemagglutinin (anti-FHA), and anti-pertactin (anti-PRN) were determined using ELISA on solid phase based on sandwich principle.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"132.6","spread":null},{"groupId":"OG001","value":"139.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"210.9","spread":null},{"groupId":"OG001","value":"189.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"310.0","spread":null},{"groupId":"OG001","value":"259.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":474},"commonTop":["Injection site erythema","Pyrexia","Injection site pain","Injection site swelling","Nasopharyngitis"]}}}